Follow
Marie-Karelle RIVIERE
Marie-Karelle RIVIERE
Saryga
No verified email
Title
Cited by
Cited by
Year
On multi-armed bandit designs for dose-finding trials
M Aziz, E Kaufmann, MK Riviere
Journal of Machine Learning Research 22 (14), 1-38, 2021
75*2021
A Bayesian dose‐finding design for drug combination clinical trials based on the logistic model
MK Riviere, Y Yuan, F Dubois, S Zohar
Pharmaceutical statistics 13 (4), 247-257, 2014
682014
Designs of drug-combination phase I trials in oncology: a systematic review of the literature
MK Riviere, C Le Tourneau, X Paoletti, F Dubois, S Zohar
Annals of Oncology 26 (4), 669-674, 2015
622015
Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization
MK Riviere, Y Yuan, JH Jourdan, F Dubois, S Zohar
Statistical methods in medical research 27 (2), 466-479, 2018
552018
Competing designs for drug combination in phase I dose‐finding clinical trials
MK Riviere, F Dubois, S Zohar
Statistics in medicine 34 (1), 1-12, 2015
472015
A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent
MK Riviere, Y Yuan, F Dubois, S Zohar
Journal of the Royal Statistical Society: Series C (Applied Statistics) 64 …, 2015
442015
An MCMC method for the evaluation of the Fisher information matrix for non-linear mixed effect models
MK Riviere, S Ueckert, F Mentré
Biostatistics 17 (4), 737-750, 2016
222016
Bayesian methods for the analysis of early‐phase oncology basket trials with information borrowing across cancer types
J Jin, MK Riviere, X Luo, Y Dong
Statistics in Medicine 39 (25), 3459-3475, 2020
202020
Cephalometric assessment of craniofacial dysmorphologies in relation with Msx2 mutations in mouse
Y Simon, A Marchadier, MK Riviere, K Vandamme, F Koenig, F Lezot, ...
Orthod Craniofac Res. 17 (2), 92-105, 2014
182014
Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
E Gerard, S Zohar, HT Thai, C Lorenzato, MK Riviere, M Ursino
Biometrics 78 (1), 300-312, 2022
112022
Robust designs in longitudinal studies accounting for parameter and model uncertainties–application to count data
F Loingeville, TT Nguyen, MK Riviere, F Mentré
Journal of biopharmaceutical statistics 30 (1), 31-45, 2020
112020
Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens
E Gerard, S Zohar, C Lorenzato, M Ursino, M Riviere
Statistics in Medicine 40 (23), 5096-5114, 2021
62021
dfcomb: An R-package for phase I/II trials of drug combinations
MK Riviere, JH Jourdan, S Zohar
Computer methods and programs in biomedicine 125, 117-133, 2016
22016
Improved Confidence Intervals and P-Values by Sampling from the Normalized Likelihood
S Ueckert, MK Riviere, F Mentre
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 42, S56-S57, 2015
22015
Response to comments on ‘Competing designs for drug combination in phase I dose‐finding clinical trials’ by G. Yin, R. Lin and N. Wages
MK Riviere, F Dubois, S Zohar
Statistics in medicine 34 (1), 23-26, 2015
12015
Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
E Gerard, S Zohar, HT Thai, C Lorenzato, MK Riviere, M Ursino
Biometrics 78 (1), 300-312, 2022
2022
Modélisation bayésienne d’une toxicité bivariée en essais de phase précoce en oncologie évaluant des régimes de dose
E Gérard, S Zoha, M Ursino, M Rivière
Revue d'Épidémiologie et de Santé Publique 69, S13-S14, 2021
2021
Comments on ‘A comparative study of adaptive dose‐finding designs for phase I oncology trials of combination therapies’
MK Riviere, S Zohar
Statistics in Medicine 35 (3), 475-478, 2016
2016
Designs adaptifs de recherche de dose en oncologie dans le cadre de combinaisons de molécules et de molécules ciblées
MK Rivière
Paris 7, 2014
2014
Bandit Algorithms for Early-Stage Clinical Trials
E Kaufmann, M Aziz, MK Riviere
The system can't perform the operation now. Try again later.
Articles 1–20